Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Processa Pharmaceuticals Inc PCSA

Healthcare Biotechnology
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC... see more

Recent & Breaking News (NDAQ:PCSA)

Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST

GlobeNewswire May 5, 2022

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

GlobeNewswire April 20, 2022

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

GlobeNewswire April 5, 2022

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

GlobeNewswire March 30, 2022

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

GlobeNewswire March 23, 2022

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 10, 2022

Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022

GlobeNewswire January 26, 2022

Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update

GlobeNewswire November 11, 2021

Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis

GlobeNewswire November 4, 2021

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST

GlobeNewswire October 26, 2021

Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis

GlobeNewswire October 12, 2021

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update

GlobeNewswire September 16, 2021

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire September 16, 2021

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27

GlobeNewswire August 23, 2021

PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019

GlobeNewswire March 11, 2019

PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA

GlobeNewswire January 29, 2019

PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY

GlobeNewswire January 9, 2019

PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET

GlobeNewswire December 6, 2018

Processa Pharmaceuticals Receives FDA Clearance Of IND To Begin Phase 2 Clinical Development Of PCS-499 In Necrobiosis Lipoidica Patients

PR Newswire October 2, 2018